Han Su Jung, Lee Tae Hoon, Park Sang-Heum, Cho Young Sin, Lee Yun Nah, Jung Yunho, Choi Hyun Jong, Chung Il-Kwun, Cha Sang-Woo, Moon Jong Ho, Cho Young Deok, Kim Sun-Joo
Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University School of Medicine, Cheonan, South Korea.
Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon, South Korea.
Dig Endosc. 2017 May;29(3):369-376. doi: 10.1111/den.12841. Epub 2017 Mar 6.
As society ages, the need for endoscopic retrograde cholangiopancreatography (ERCP) is increasing. This prospective comparative study evaluated the safety and efficacy of midazolam- versus propofol-based sedations by non-anesthesiologists during therapeutic ERCP in patients over 80 years of age.
A total of 100 patients over 80 years of age who required therapeutic ERCP were enrolled and randomly received midazolam + fentanyl (MF group) or propofol + fentanyl (PF group) sedation. Endoscopic sedation was titrated to a moderate level and carried out by trained registered nurses. Main outcome measurements were sedation safety in terms of cardiopulmonary components and efficacy measured on a 10-point visual analogue scale (VAS).
Regarding safety, hypoxia occurred in seven (14%) in the MF group and in eight patients (16%) in the PF group (P = 0.779). Increased O supply was more frequent in the PF group (32% vs 42%), albeit not significantly so. There were no differences in the frequency of hypotension, bradycardia or tachycardia between the two groups. Mean VAS score for overall satisfaction with sedation by patients, endoscopists, and nurses and the scores for pain during the procedures were not different between the two groups. There was no significant difference in the procedure outcomes or rate of ERCP-related complications.
There were no significant differences of safety and efficacy between midazolam- and propofol-based sedation in patients over 80 years of age. Increased O supply was more frequent in the propofol group, but the prevalence of hypoxia did not differ significantly.
随着社会老龄化,内镜逆行胰胆管造影术(ERCP)的需求日益增加。本前瞻性对照研究评估了非麻醉医生在80岁以上患者治疗性ERCP期间使用咪达唑仑与丙泊酚镇静的安全性和有效性。
共有100例80岁以上需要治疗性ERCP的患者入组,并随机接受咪达唑仑+芬太尼(MF组)或丙泊酚+芬太尼(PF组)镇静。内镜镇静滴定至中度水平,由经过培训的注册护士进行。主要观察指标为心肺指标方面的镇静安全性以及用10分视觉模拟量表(VAS)测量的有效性。
在安全性方面,MF组7例(14%)出现低氧血症,PF组8例(16%)出现低氧血症(P = 0.779)。PF组增加氧气供应的情况更频繁(32%对42%),尽管差异无统计学意义。两组间低血压、心动过缓或心动过速的发生率无差异。患者、内镜医师和护士对镇静总体满意度的平均VAS评分以及操作过程中的疼痛评分在两组间无差异。操作结果或ERCP相关并发症发生率无显著差异。
80岁以上患者中,基于咪达唑仑和丙泊酚的镇静在安全性和有效性方面无显著差异。丙泊酚组增加氧气供应的情况更频繁,但低氧血症的发生率无显著差异。